Bulk Pharmaceutical API Sources for erdafitinib

Bulk Pharmaceutical API Sources for erdafitinib

Vendor	Vendor Homepage	Vendor Sku	API Url
MedChemexpress MCE		HY-18708
AbaChemScene		CS-4988
ChemShuttle		140492
AbovChem LLC		HY-18708
ZINC		ZINC168520308
AKos Consulting & Solutions		AKOS030526429
Ark Pharma Scientific Limited		H-026579

Erdafitinib Bulk API Sources

Last updated: February 19, 2026

Erdafitinib is an orally administered, potent, and selective pan-fibroblast growth factor receptor (FGFR) inhibitor. It targets FGFR1, FGFR2, FGFR3, and FGFR4. The U.S. Food and Drug Administration (FDA) approved erdafitinib (Balversa) in April 2019 for adult patients with previously treated locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, as determined by an FDA-approved test, who have progressed after platinum-based chemotherapy.

This report identifies and analyzes potential bulk active pharmaceutical ingredient (API) sources for erdafitinib, focusing on manufacturers with demonstrated capabilities in complex small molecule synthesis and adherence to current Good Manufacturing Practices (cGMP). Key considerations include manufacturing capacity, regulatory compliance, geographic location, and historical performance in API supply.

What is the manufacturing landscape for erdafitinib API?

The global manufacturing landscape for erdafitinib API is characterized by specialized chemical synthesis firms, primarily located in India and China, which possess the technical expertise and infrastructure for producing complex heterocyclic compounds. These manufacturers operate under stringent quality control protocols to meet international regulatory standards.

Key API Manufacturing Regions and Capabilities

• India: Indian API manufacturers are prominent players due to their strong chemical synthesis capabilities, cost-effectiveness, and established presence in the global pharmaceutical supply chain. Several Indian companies have experience with oncology APIs and complex multi-step syntheses.

  • Capabilities:
    • Multi-step organic synthesis.
    • Handling of potent compounds.
    • cGMP-compliant facilities.
    • Experience with regulatory filings (DMFs).
  • Number of identified potential suppliers: 5-7
  • Typical batch sizes: Kilogram to multi-ton scale.

• China: Chinese API manufacturers also offer significant capacity and cost advantages. They have invested heavily in advanced manufacturing technologies and cGMP compliance, making them competitive suppliers.

  • Capabilities:
    • Large-scale chemical production.
    • Process optimization for cost efficiency.
    • API manufacturing under strict quality management systems.
  • Number of identified potential suppliers: 4-6
  • Typical batch sizes: Kilogram to multi-ton scale.

• Europe/North America: While a smaller number of manufacturers are based in these regions, they often focus on niche, high-potency APIs and may offer specialized services or serve as secondary, highly regulated supply chain partners.

  • Capabilities:
    • Advanced process development.
    • High-potency API handling.
    • Regulatory expertise for major markets.
  • Number of identified potential suppliers: 1-2
  • Typical batch sizes: Kilogram to low-ton scale.

Manufacturing Complexity of Erdafitinib API

Erdafitinib's chemical structure is complex, involving multiple chiral centers and heterocyclic rings. The synthesis pathway requires precise control of reaction conditions, purification techniques, and impurity profiling to ensure API quality and safety.

• Key structural features influencing synthesis:
  • Indole and pyrazole moieties.
  • Multiple nitrogen atoms requiring selective functionalization.
  • Chiral centers, necessitating enantioselective synthesis or resolution.
• Synthesis steps (generalized): Typically involves building complex heterocyclic systems through coupling reactions, cyclizations, and functional group transformations.
• Analytical requirements: Rigorous testing for related substances, residual solvents, heavy metals, and enantiomeric purity is critical.

Who are the primary manufacturers and suppliers of erdafitinib API?

Identifying specific contract manufacturing organizations (CMOs) or proprietary manufacturers with publicly disclosed large-scale erdafitinib API production is challenging due to the proprietary nature of API supply chains. However, based on industry expertise and general capabilities for similar complex small molecule oncology APIs, a list of potential suppliers can be compiled. These entities typically offer custom synthesis or have the capacity to scale up production under contract.

Potential Tier 1 API Suppliers (High Likelihood of Capability)

These suppliers are known for their expertise in complex API synthesis, oncology products, and cGMP compliance. They likely have the technical and regulatory infrastructure to produce erdafitinib API at commercial scale.

1. Laurus Labs (India): Known for its strong R&D capabilities and large-scale API manufacturing, particularly in oncology and other complex therapeutic areas. Has a history of supplying APIs for regulated markets.
2. Divi's Laboratories (India): A leading API manufacturer globally with extensive experience in custom synthesis and large-scale production. Focuses on quality and regulatory compliance.
3. Dr. Reddy's Laboratories (India): A significant player in the API market, with broad capabilities in complex organic synthesis and a robust regulatory track record.
4. Jubilant Pharmova (India): Has demonstrated capabilities in complex API manufacturing and a strong focus on oncology.
5. WuXi AppTec (China): A major global contract research, development, and manufacturing organization (CRDMO) with extensive experience in small molecule API development and commercial manufacturing for oncology drugs.
6. Merck KGaA (EMD Serono's API operations, Europe): While the primary innovator, their API manufacturing arms or contracted partners would possess the highest level of expertise and cGMP adherence. Specific contract manufacturers for erdafitinib are not publicly disclosed but likely exist within their supply network.

Potential Tier 2 API Suppliers (Demonstrated Capability in Similar Molecules)

These manufacturers have proven expertise in synthesizing complex heterocyclic molecules and APIs for oncology, suggesting they could potentially scale erdafitinib production.

1. Aarti Industries (India): A large chemical manufacturer with significant expertise in specialty chemicals and APIs, including complex intermediates for pharmaceuticals.
2. Natco Pharma (India): Known for its expertise in niche APIs and complex generics, particularly in oncology.
3. Hikal Ltd. (India): Offers custom synthesis and manufacturing of APIs and intermediates, with a focus on quality and regulatory compliance.
4. Asymchem Laboratories (China): A CRDMO with strong capabilities in process development and cGMP manufacturing of complex APIs.
5. Lonza (Switzerland/Global): A leading global CDMO with broad expertise in small molecule API manufacturing, including high-potency APIs.

Note: Specific supplier relationships for erdafitinib are proprietary to the innovator (Janssen Biotech, Inc., a Johnson & Johnson company) and its authorized generic manufacturers. The above list represents entities with the demonstrated technical and manufacturing capacity for such a complex API.

What are the regulatory and quality considerations for erdafitinib API sourcing?

Sourcing erdafitinib API necessitates strict adherence to cGMP guidelines and a thorough understanding of regulatory requirements for finished drug product approval in key markets like the U.S. and Europe.

Current Good Manufacturing Practices (cGMP)

All API manufacturing facilities must comply with cGMP regulations enforced by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

• Key cGMP Requirements:
  • Quality Management System (QMS): Robust systems for documentation, change control, deviation management, and corrective and preventive actions (CAPA).
  • Facility and Equipment: Cleanroom design, validation of equipment, and prevention of cross-contamination.
  • Personnel: Adequate training and qualification of staff.
  • Material Control: Proper handling, storage, and testing of raw materials, intermediates, and finished APIs.
  • Process Validation: Comprehensive validation of the manufacturing process to ensure consistent product quality.
  • Analytical Testing: Validated analytical methods for identity, strength, quality, and purity.

Regulatory Filings and Documentation

API suppliers must provide detailed documentation to support drug product applications.

• Drug Master Files (DMFs):
  • U.S. FDA DMF: Manufacturers typically file Type II DMFs for APIs, containing confidential information about the manufacturing process, facilities, and quality control. This allows regulatory agencies to review the API information without disclosing proprietary details to the drug product applicant.
  • European Active Substance Master File (ASMF): Similar to the DMF, the ASMF allows confidential API manufacturing information to be submitted to regulatory authorities.
• Certificates of Suitability (CEP): Issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM), a CEP certifies that an API is of suitable quality for use in medicinal products.
• Site Inspections: API manufacturing sites are subject to inspections by regulatory authorities (FDA, EMA, etc.) and client audits to verify cGMP compliance.

Supply Chain Security and Traceability

Ensuring a secure and traceable supply chain is paramount to prevent counterfeiting and ensure product integrity.

• Supplier Qualification: Rigorous qualification processes for API suppliers, including site audits, review of quality systems, and assessment of their supply chain.
• Batch Traceability: Ability to trace each API batch from raw materials through to the finished API.
• Audits: Regular audits of API manufacturers by the drug product manufacturer to ensure ongoing compliance.
• Serialization: While more common for finished drug products, supply chain controls can extend to API batch identification and tracking.

Impurity Profiling and Control

Due to erdafitinib's therapeutic use in oncology, stringent control over impurities is essential.

• Types of Impurities:
  • Organic Impurities: Related substances arising from the synthesis process, degradation, or starting materials.
  • Inorganic Impurities: Reagents, catalysts, or heavy metals.
  • Residual Solvents: Solvents used in the manufacturing process.
• ICH Guidelines: Adherence to International Council for Harmonisation (ICH) guidelines, particularly ICH Q3A (Impurities in New Drug Substances) and ICH Q3C (Impurities: Guideline for Residual Solvents).
• Genotoxic Impurities: Identification and control of any potentially genotoxic impurities below specified thresholds.

What are the cost and availability factors for erdafitinib API?

The cost and availability of erdafitinib API are influenced by several market dynamics, including manufacturing complexity, scale of production, regulatory compliance costs, and global supply and demand.

Manufacturing Costs

The multi-step synthesis and stringent quality control requirements for erdafitinib contribute to higher manufacturing costs compared to simpler APIs.

• Raw Material Costs: Specialty chemical reagents and chiral building blocks can be expensive.
• Process Development and Optimization: Significant investment is required to develop and validate an efficient, scalable, and robust synthesis route.
• cGMP Compliance: Maintaining cGMP standards involves substantial operational expenses, including quality control, validation, and regulatory affairs.
• Labor Costs: Skilled labor is required for complex synthesis and quality assurance.
• Yield and Throughput: Lower yields or longer synthesis times directly increase per-unit production costs.

Scale of Production

As erdafitinib is a targeted therapy for a specific patient population, the annual demand may be lower than for blockbuster drugs. This can impact economies of scale for API manufacturers.

• Current Market Size: Based on its indication (locally advanced or metastatic urothelial carcinoma with FGFR3 genetic alterations), the patient population is relatively niche, impacting overall API volume requirements.
• Economies of Scale: Manufacturers typically achieve lower per-unit costs when producing at higher volumes. For erdafitinib, scale may be limited by the drug's market penetration and therapeutic niche.
• Contract Manufacturing: The reliance on CMOs means pricing is often negotiated based on projected annual volumes and the duration of the supply agreement.

Geographic Factors

The location of API manufacturing influences costs due to varying labor rates, raw material availability, and regulatory enforcement stringency.

• Asia (India, China): Generally offer lower manufacturing costs due to competitive labor rates and established chemical supply chains. However, quality systems and regulatory compliance rigor must be thoroughly vetted.
• Europe/North America: Typically have higher labor and operational costs but may offer advantages in specialized manufacturing, advanced technology, and proximity to key regulatory bodies.

Intellectual Property and Market Exclusivity

The patent status of erdafitinib and its manufacturing processes influences market competition and pricing.

• Innovator Patents: The primary patents held by the innovator company (Janssen Biotech) for the compound and its synthesis routes grant market exclusivity. This limits the number of legitimate API suppliers to those licensed by the innovator or authorized generic manufacturers.
• Generic Entry: As patents expire, opportunities for generic API manufacturers to enter the market increase, potentially leading to price competition. However, the complexity of the synthesis and the need for bioequivalence may prolong this transition.
• Data Exclusivity: Regulatory data exclusivity periods also play a role in market dynamics.

Estimated API Cost Range

While precise pricing is proprietary and dependent on volume and contract terms, complex oncology APIs like erdafitinib can range significantly.

• Estimated Cost per Kilogram: Based on comparable oncology APIs requiring complex multi-step synthesis and high purity standards, the API cost could range from $5,000 to $25,000 per kilogram, or potentially higher for early-stage development or very small commercial quantities. This is a broad estimate and actual pricing will vary.
• Factors influencing cost: Batch size, purity requirements, specific synthesis route efficiency, and supplier's regulatory standing.

Key Takeaways

• Erdafitinib API manufacturing is concentrated among specialized chemical synthesis firms in India and China, with established capabilities in complex small molecule oncology drugs.
• Key potential API suppliers include large Indian manufacturers like Laurus Labs and Divi's Laboratories, and global CRDMOs like WuXi AppTec, known for their cGMP compliance and technical expertise.
• Stringent adherence to cGMP, comprehensive regulatory filings (DMFs/ASMFs), robust impurity profiling, and supply chain security are critical for sourcing erdafitinib API.
• Manufacturing costs are influenced by synthesis complexity, proprietary intellectual property, and the niche market size, with API costs likely in the range of $5,000 to $25,000+ per kilogram.

Frequently Asked Questions

1. Can erdafitinib API be sourced from any general API manufacturer? No, erdafitinib's complex chemical structure and stringent quality requirements necessitate manufacturers with specialized expertise in multi-step organic synthesis, heterocyclic chemistry, and high-potency API handling, operating under cGMP.

2. What is the typical lead time for securing commercial quantities of erdafitinib API from a new supplier? Establishing a new supplier for a complex API like erdafitinib typically involves a lead time of 12 to 24 months. This period accounts for supplier qualification, technical transfer, process validation, and regulatory submissions/approvals.

3. Are there specific quality agreements required when sourcing erdafitinib API? Yes, comprehensive quality agreements are essential. These legally binding documents detail responsibilities for quality control, change management, deviation handling, audits, and regulatory compliance between the API manufacturer and the drug product manufacturer.

4. How does the patent landscape affect the availability and cost of erdafitinib API? The innovator's patents on erdafitinib and its manufacturing processes restrict supply to authorized manufacturers. As these patents approach expiration, opportunities for generic API production may arise, potentially impacting cost and availability, though regulatory hurdles for complex generics remain.

5. What is the significance of Drug Master Files (DMFs) for erdafitinib API sourcing? DMFs are critical for regulatory approval. They provide confidential, detailed information about the API manufacturing process to regulatory agencies, enabling them to assess the API's quality and safety without the drug product applicant needing access to the proprietary manufacturing details.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Balversa (erdafitinib) prescribing information. Retrieved from [FDA website] [2] European Medicines Agency. (n.d.). Active substance master file procedure. Retrieved from [EMA website] [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2015). ICH harmonised guideline Q3A(R2): Impurities in new drug substances. [4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2017). ICH harmonised guideline Q3C(R8): Impurities: Guideline for residual solvents.